News
Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 ...
A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...
GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...
(HealthDay News) — A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a ...
1d
HealthDay on MSN1 in 10 Americans Has Used GLP-1 Drugs For Weight Loss, Survey SaysKey Takeaways More than 1 in 10 Americans has tried a GLP-1 drug50- to 64-year-olds report the most useSide effects like ...
Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...
ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...
1d
Clinical Trials Arena on MSNEli Lilly’s oral GLP-1RA hits endpoints, but trails Novo’s Wegovy in weight lossOrforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...
GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results